Financial reports
10-Q
2025 Q2
Quarterly report
5 Dec 24
10-Q
2025 Q1
Quarterly report
5 Sep 24
ARS
2024 FY
Annual report to shareholders
22 Aug 24
10-K
2024 FY
Annual report
11 Jul 24
10-Q
2024 Q3
Quarterly report
11 Mar 24
10-Q
2024 Q2
Quarterly report
7 Dec 23
10-Q
2024 Q1
Quarterly report
7 Sep 23
ARS
2023 FY
Annual report to shareholders
14 Aug 23
10-K
2023 FY
Annual report
7 Jul 23
10-Q
2023 Q3
Quarterly report
9 Mar 23
Current reports
8-K
KalVista Appoints Jeb Ledell as Chief Operating Officer
16 Dec 24
8-K
KalVista Pharmaceuticals Reports Second Fiscal Quarter Results and Provides Operational Update
5 Dec 24
8-K
KalVista Pharmaceuticals Appoints Laurence Reid, Ph.D., to Board of Directors
26 Nov 24
8-K
KalVista Pharmaceuticals Announces Pricing of a $55 Million Underwritten Offering of Common Stock and Concurrent Private Placement of $5 Million
4 Nov 24
8-K
Entry into a Material Definitive Agreement
4 Nov 24
8-K
Submission of Matters to a Vote of Security Holders
4 Oct 24
8-K
KalVista Appoints Brian Piekos as Chief Financial Officer
10 Sep 24
8-K
KalVista Pharmaceuticals Reports First Fiscal Quarter Results and Provides Operational Update
5 Sep 24
8-K
Entry into a Material Definitive Agreement
23 Jul 24
8-K
KalVista Pharmaceuticals Provides Operational Update and Fiscal Year Financial Results
11 Jul 24
Registration and prospectus
S-8
Registration of securities for employees
16 Jan 25
424B5
Prospectus supplement for primary offering
4 Nov 24
S-3
Shelf registration
11 Jul 24
S-8
Registration of securities for employees
28 Jun 24
424B5
Prospectus supplement for primary offering
16 Feb 24
424B5
Prospectus supplement for primary offering
14 Feb 24
S-8
Registration of securities for employees
9 Jan 24
S-8
Registration of securities for employees
20 Jun 23
S-8
Registration of securities for employees
10 Jan 23
424B5
Prospectus supplement for primary offering
27 Dec 22
Proxies
DEFA14A
Additional proxy soliciting materials
22 Aug 24
DEF 14A
Definitive proxy
22 Aug 24
DEFA14A
Additional proxy soliciting materials
14 Aug 23
DEF 14A
Definitive proxy
14 Aug 23
PRE 14A
Preliminary proxy
4 Aug 23
DEFA14A
Additional proxy soliciting materials
11 Oct 22
DEFA14A
Additional proxy soliciting materials
22 Aug 22
DEF 14A
Definitive proxy
22 Aug 22
DEFA14A
Additional proxy soliciting materials
17 Aug 21
DEF 14A
Definitive proxy
17 Aug 21
Other
EFFECT
Notice of effectiveness
22 Jul 24
EFFECT
Notice of effectiveness
2 Jun 21
CORRESP
Correspondence with SEC
27 May 21
UPLOAD
Letter from SEC
27 May 21
EFFECT
Notice of effectiveness
24 Dec 18
CORRESP
Correspondence with SEC
20 Dec 18
UPLOAD
Letter from SEC
20 Dec 18
CT ORDER
Confidential treatment order
13 Mar 18
EFFECT
Notice of effectiveness
28 Apr 17
CORRESP
Correspondence with SEC
27 Apr 17
Ownership